Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
PHASE3CompletedINTERVENTIONAL
Enrollment
203
Participants
Timeline
Start Date
September 30, 2015
Primary Completion Date
February 28, 2017
Study Completion Date
June 30, 2017
Conditions
Immune Thrombocytopenia
Interventions
DRUG
Romiplostim
DRUG
Placebo
Trial Locations (1)
Unknown
Peking Union Medical College Hospital, Beijing
All Listed Sponsors
lead
Kyowa Kirin China Pharmaceutical Co., Ltd.
INDUSTRY
NCT02868099 - Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter